Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ENSC
Ensysce Biosciences, Inc. Common Stock
stock NASDAQ

At Close
Aug 22, 2025 3:59:30 PM EDT
2.07USD0.000%(0.00)74,452
0.00Bid   0.00Ask   0.00Spread
Pre-market
Aug 22, 2025 8:57:30 AM EDT
2.06USD-0.483%(-0.01)200
After-hours
Aug 20, 2025 4:38:30 PM EDT
2.06USD-0.324%(-0.01)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
04:01PM EST  Ensysce Biosciences Engages MZ Group to Lead Strategic Investor   GlobeNewswire Inc
Jan 27, 2022
08:30AM EST  Ensysce Biosciences Announces Results of Special Meeting of   GlobeNewswire Inc
Jan 19, 2022
04:19PM EST  Ensysce Biosciences Reminds Stockholders to Vote at Upcoming   GlobeNewswire Inc
Jan 10, 2022
08:17AM EST  Ensysce Biosciences Announces First Cohort Dosing In Bioequivalence Study Of Novel 'TAAP' Opioid   Benzinga
08:00AM EST  Ensysce Biosciences Announces First Cohort Dosing in   GlobeNewswire Inc
Jan 5, 2022
04:05PM EST  Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced managements participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.   GlobeNewswire Inc
Jan 4, 2022
08:05AM EST  Ensysce Biosciences Reports Achieved Successful Completion Of Part A Of Multiple-Ascending Dose/Bioequivalents Trial For PF614   Benzinga
08:00AM EST  Ensysce Biosciences Achieves Successful Completion of Part A of   GlobeNewswire Inc
Dec 22, 2021
03:46PM EST  Ensyce Biosciences Resume Trading After Circuit Breaker Halt   Benzinga
Dec 15, 2021
04:10PM EST  Ensysce Biosciences Announces First Patients Enrolled In Phase 1 Study Of PF614-MPAR, Its Unique Technology Platform To Provide Opioid Overdose Protection   Benzinga
04:05PM EST  Ensysce Biosciences Announces First Patients Enrolled in Phase 1   GlobeNewswire Inc
Dec 14, 2021
08:52AM EST  ENSC: Tackling the Opioid Crisis   Benzinga
Dec 9, 2021
09:50PM EST  Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low   Benzinga
09:45PM EST  Ensysce Biosciences Shares Up $53% Premarket; Zacks Small-Cap Research Gave Stock $23 Price Valuation on Tuesday   Benzinga
Dec 8, 2021
10:16AM EST  Mid-Morning Market Update: Markets Mixed; United Natural Foods Beats Q1 Views   Benzinga
Nov 30, 2021
04:53PM EST  Lake Street Initiates Coverage On Ensysce Biosciences with Buy Rating, Announces Price Target of $4   Benzinga
04:44PM EST  Ensysce Biosciences Announces Clinical Trial Progress Of Its New Class Of Opioids   Benzinga
08:00AM EST  Ensysce Biosciences Announces Clinical Trial Progress of its New   GlobeNewswire Inc
Nov 15, 2021
06:53PM EST  Ensysce Biosciences Q3 Net Loss $17.2M vs Net Income $1.6M In Same Qtr. Last Year   Benzinga
Nov 8, 2021
08:00AM EST  Ensysce Biosciences Announces Completion of $15 Million   GlobeNewswire Inc
Oct 26, 2021
08:00AM EDT  Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 27, 2021
08:00AM EDT  Ensysce Biosciences Announces $15 Million Convertible Note Financing   GlobeNewswire Inc
Sep 8, 2021
08:05AM EDT  Ensysce Biosciences Enrolls First Cohort Of Subjects In A Clinical Study PF614-102   RTTNews
08:00AM EDT  Ensysce Biosciences Announces Treatment of First Cohort for   GlobeNewswire Inc
Aug 20, 2021
06:03AM EDT  Pre-market Movers: GOVX, PROG, SONN, MRIN,   RTTNews
Aug 19, 2021
10:20AM EDT  Mid-Morning Market Update: Markets Mostly Flat; Este Lauder Sales Top Views   Benzinga
08:00AM EDT  Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey   GlobeNewswire Inc
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
04:55PM EDT  Ensysce Biosciences Q2 Net Loss $1M   Benzinga
04:47PM EDT  Ensysce Biosciences Reports Q2 Net Loss $1M Compared To $700K YoY   Benzinga
04:45PM EDT  Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.   GlobeNewswire Inc
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 5, 2021
08:18AM EDT  Ensysce Biosciences Highlights Notice Of Allowance From US Patent & Trademark Office For 'Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof'   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 26, 2021
08:00AM EDT  Ensysce Biosciences Bolsters Management Team with Appointments of   GlobeNewswire Inc
Jul 22, 2021
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
Jul 21, 2021
08:00AM EDT  Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that it will host a virtual investor day on Tuesday, July 27, 2021 from 11:00 am to 12:00 pm EDT.   GlobeNewswire Inc
07:52AM EDT  The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
08:17AM EDT  Ensysce Biosciences Receives Notice of Award For 3 Of Multi-Year National Institute On Drug Abuse Grant For Clinical Development Of Next Generation Opioid Products With Overdose Protection; Grant Will Provide $2.8M For Phase 1 Study   Benzinga
08:00AM EDT  Ensysce Biosciences Receives Notice of Award for Year Three of   GlobeNewswire Inc
Jul 1, 2021
04:41PM EDT  Ensysce Biosciences To Begin Trading On Nasdaq On July 2   Benzinga
Jun 30, 2021
04:23PM EDT  Ensysce Biosciences Announces Closing of Merger   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC